Ann: Admedus to host Investor Webinar, page-56

You really are sailing close to the wind here Russ. You know nothing about who I am. So I would appreciate you keeping your groundless suspicions to yourself.
I will simplify things for you.

Consolidation is going to reduce all holdings by 10 to 1. Meaning we all will own 10% by number of shares we now hold.
I think that this is the only solution to the dilution mess that has been created since the backdoor takeover.
My holding has been diluted 900%. I have a right to feel a little stitched up. However I am clearly offering a solution that will benefit all share holders if you have the capacity to think outside the square.

So. If consolidation is passed then my suggestion was and is that:
1.We keep Admedus and keep the management and continue to run with 183 million shares on issue with the capacity to raise capital as set out in the AGM proposal.
2. We create a second public company and we split off that company ,either the Vaccine or the CC, and run it as a separate entity ,and capital raise within that company for that product. Lets call the new company Medvac ( vaccines) and keep Admedus ( ADAPT tissue engineering CC).
3. For every share held in Admedus the share holders would receive one share in Medvac. So if you held 500,000 shares after the consolidation of Admedus then after the split you would hold (500,000 shares in Medvac plus 500,000 shares in Admedus).
4. Strategically it is good move because you can attract investors who have focus on one or the other.

This is a win for all share holders. We end up with equal shares in both companies. No-one loses.
It also means you have two companies which doubles the capacity to raise money.
It means one area of the business does not drain funds from the other area.
It is not that hard to achieve.

I do not know why this proposal would upset you Russ. I am trying to offer a solution to the dilution as well as provide some benefit to shareholders.